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With recent advances in genotyping and sequencing technologies, many disease susceptibility loci have been identified. How-
ever, much of the genetic heritability remains unexplained and the replication rate between independent studies is still low. 
Meanwhile, there have been increasing efforts on functional annotations of the entire human genome, such as the Encyclopedia 
of DNA Elements (ENCODE) project and other similar projects. It has been shown that incorporating these functional annota-
tions to prioritize genome wide association signals may help identify true association signals. However, to our knowledge, the 
extent of the improvement when functional annotation data are considered has not been studied in the literature. In this article, 
we propose a statistical framework to estimate the improvement in replication rate with annotation data, and apply it to 
Crohn’s disease and DNase I hypersensitive sites. The results show that with cell line specific functional annotations, the ex-
pected replication rate is improved, but only at modest level. 
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In recent years, the genetic basis of many traits/diseases 
have been studied through genome wide association studies 
(GWAS), resulting in the identifications of tens of thou-
sands of loci that are associated with hundreds of 
traits/diseases at genome-wide significance level [1]. The 
number of loci with moderate or suggestive association ev-
idence is even larger, and it is reasonable to anticipate that 
some of these loci will achieve genome wide significance 
when more samples are collected and analyzed. It is critical 
to develop statistical methods to prioritize regions with sim-
ilar association evidence to improve the replication rate in 
follow-up studies so as to achieve genome level statistical 
significance. In this article, we will focus on the analysis of 
single nucleotide polymorphisms (SNPs) as they constitute 
the largest class of variants used in GWAS. The procedure 
to select SNPs for follow-up studies is called post-GWAS 
prioritization [2], which aims to identify SNPs that are more 
likely to replicate by incorporating external information. 
Informative resources include linkage analysis results, 
GWAS results of a second cohort, biological pathway data-
bases, evidence in medical literature, and functional annota-
tions such as expression quantitative trait loci (eQTL), 
non-synonymous variation, and others [3].  
Intuitively, the external information should prove useful 
in prioritizing GWAS results and researchers have found 
evidence that GWAS results are enriched in the sets of 
SNPs functionally annotated. Minelli et al. [4] conducted a 
survey among experts in the genetics field, asking them to  
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score the importance of different information resources 
when they choose SNPs for follow-up experiments in their 
research. The results showed that gene level characteristics, 
such as “the SNP is in a gene which is highly expressed in a 
tissue relevant to the phenotype” and “the SNP is in a gene 
which encodes for a protein in a pathway relevant to the 
phenotype”, were thought as most important by experts. 
Indeed, prioritization based on gene level evidence has been 
explicitly employed in GWAS of complex diseases, for 
example, rheumatoid arthritis [5] and breast cancer [6]. In 
contrast, functional annotations that are not gene centric, 
like transcription factor binding sites, DNase I hypersensi-
tive sites, and histone modifications, are not as frequently 
exploited, despite the considerable biological relevance. In 
this article, we use functional annotation to refer to a collec-
tion of chromosomal regions in the human genome impli-
cated in a functional assay such as ChIP-seq, DHS-seq, and 
others. There is a need for effective computational ap-
proaches to prioritizing GWAS results using functional an-
notations because 44% of trait/disease susceptibility loci 
documented in the NHGRI GWAS catalogue as 12/03/13 [1] 
are located in intergenic regions, which could be overlooked 
by gene centric methods, and much can be learned of the 
functional roles of these loci from the rapidly increasing 
functional annotation data of the non-coding regions. For 
example, the epigenome mapping by the Encyclopedia of 
DNA Elements (ENCODE) project [7] and the Roadmap 
Epigenomics Program [8] has generated large experimental 
data in a variety of human cell lines and tissues. Research-
ers hope that these datasets would help to decipher the func-
tional relevance of non-coding SNPs and disease etiology. 
In addition, prioritization based on functional annotations is 
more likely to obtain novel findings as opposed to 
gene-based characteristics, since the latter may be biased to 
the “known” biology of the trait/disease. There are various 
web servers that provide annotation information for SNPs 
on many genomic features [3].  
Although proper incorporation of many types of func-
tional annotation data can better prioritize SNPs for fol-
low-up studies, there are a number of unsolved questions 
that may hinder the developments and applications of effec-
tive prioritization strategies using functional annotation data. 
First, among many types of functional assays in various cell 
lines, which are more informative for the trait/disease of 
interest? In other words, how to select appropriate annota-
tion data to prioritize SNPs to increase replication rate in 
follow-up studies? Second, how much improvement, in 
terms of replication rate, can we expect by incorporating 
such information? Obviously, the answers to these questions 
will depend on the specific diseases to be studied and 
available functional annotation data. In this paper, we at-
tempt to address these questions by taking Crohn’s disease 
and DNase I hypersensitive sites (DHSs) as an example. We 
show that when appropriate functional annotation data are 
incorporated, the replication rate for the prioritized SNPs 
may be improved. The degree of improvement is annotation 
specific, but the level of improvement is only modest for the 
existing annotation data. Therefore, other information and 
approaches are needed to better prioritize SNPs with a sig-
nificantly improved replication rate. 
1  Methods 
1.1  GWAS datasets of Crohn’s disease 
The p-values in the NIDDK study were downloaded from 
dbGaP (phs000130.v1.p1). The genotype data of the 
WTCCC cohort were downloaded from the Wellcome Trust 
Case Control Consortium. In order to match the SNPs with 
the NIDDK cohort, the genotypes of the WTCCC study 
were imputed by IMPUTE2 [9], after pre-phasing by 
SHAPEIT [10]. The Phase 1 haplotypes from the 1000 Ge-
nomes project were used as the reference panel [11]. The 
association p-values of the WTCCC study were calculated 
by linear regression model, after adjusting for population 
stratification covariates (eq. (1)). In eq. (1), y denotes phe-
notype, which is 1 for cases and 0 for controls, while xi is 
the genotype of SNP i. In the regression model, *’s are 
regression coefficients, and  is the error term, which fol-
lows normal distribution. The first 10 principal components 




.i s ssy x PS        (1) 
1.2  DNase I hypersensitive sites 
DNase I hyper sensitivity is a marker for active 
cis-regulatory elements, including enhancers, promoters, 
transcription factor binding sites, and other regulatory ele-
ments. DNase I hypersensitive sites can be mapped at ge-
nome scale by DNase-seq. The analysis results of DNase- 
seq experiments of three cell lines (GSM1024760, 
GSM1024790, and GSM736556) were downloaded from 
the UCSC Genome Browser. The three cell lines are prima-
ry Th1, Th17, and normal human epidermal keratinocytes, 
respectively. Peaks with false discovery rate less than 0.01 
were used in the analysis, resulting in 268600, 159605, and 
209762 peaks in the whole genome, respectively.  
1.3  Kernel estimation of effect size distribution 
In order to estimate the effect size distribution of truly asso-
ciated SNPs in and outside of DHSs, we applied the kernel 
estimation proposed by Park et al. [12], separately to SNPs 
in DHSs of Th1 and Th17 cell lines, and to that in the whole 
genome. Briefly, to obtain an unbiased estimation of the 
effect size distribution, the effect size of SNPs which are 
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nominally significant (p-value less than 0.01) in the NIDDK 
cohort was calculated in the WTCCC cohort. Here, effect 
size is defined in eq. (2), where ˆ  is the regression coef-
ficient in eq. (1), and f is the corresponding minor allele 
frequency in the WTCCC cohort. 
 2ˆ2 (1 ).ES f f   (2) 
The density of the effect size distribution was estimated by 
kernel estimation, using the Gaussian kernel (eq. (3)), where 
( )   is the density function of standard normal distribution, 
and h is the bandwidth of the kernel. n is the number of 











       (3) 
1.4  Derivation of expected replication rate (ERR) 
The empirical definition of replication rate is the number of 
replicable SNPs divided by the number of SNPs sent for 
genotyping in the replication cohort. Accordingly, we de-
fine the theoretical replication rate in a probabilistic way, 
which is the expected number of SNPs that are replicable 
divided by the number of selected SNPs (eqs. (4) and (5)). 
We set p0 to be 0.0001. k is the number of genotyped SNPs 
in the replication study. 
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Please note 0( | )
WTCCC
i iP p p es es   is the power to de-
tect a SNP with an effect size of es in the WTCCC study. 
With the effect size given, the power of the study is fixed 
regardless of whether the SNP is in or outside DHSs. To 
ease calculation, we divide the range of the effect size dis-
tribution into L bins, 1 2{ , , , }Lbin bin bin , and the value in 
eq. (5) can be approximated via eq. (6), where the power of 
the WTCCC study of each bin was estimated as the average 
power of SNPs that fall into the corresponding interval.  
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In approach A and B, the effect size distribution was esti-
mated by all SNPs in the genome and SNPs with annota-
tions, respectively (eq. (3)). In approach C, the selected 
SNPs are a mixture of SNPs with and without annotations, 
with an unknown mixing proportion m. The expected repli-
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1.5  Calculation of the mixing proportion m with dif-
ferent coverage of annotation 
The mixing proportion is calculated by assuming the num-
ber of significant SNP with annotation is proportional to the 
coverage of the annotation. Suppose the fold change of 
coverage of SNPs with and without coverage is c1 and c2, 
and the mixing proportion in Th1 is m0, then the mixing 
proportion is 1 0
1 0 2 0(1 )
c m
c m c m  . 
2  Results 
2.1  The association signals of Crohn’s disease were 
enriched in DHSs of relevant cell lines 
Crohn’s disease is a type of inflammatory bowel diseases, 
which has been intensively studied with GWAS [1315]. 
Here we consider the GWAS results from two cohorts, 
NIDDK and WTCCC (see Materials and methods for de-
tails). T-helper cells Th1 and Th17, have been demonstrated 
to play important roles in the immunopathology of Crohn’s 
disease [16,17], thus it is interesting to ask whether the 
transcriptional regulatory elements, marked by DNase I 
hypersensitivity, in Th1 and Th17 can be used to prioritize 
association signals of Crohn’s disease. The DHSs in Th1 
and Th17 cells were mapped in the ENCODE project 
[18,19]. The DHSs dataset of normal human epidermal 
keratinocytes was included in this study as negative control, 
since it is presumably not relevant to Crohn’s disease. 
If DHSs in Th1 and Th17 are informative and helpful to 
prioritize SNPs with more replicable GWAS signals, an 
enrichment of association signals should be observed in 
such regions. In fact, among the 296561 SNPs in the two 
GWASs, 14083 and 5378 were mapped into the DHSs of 
the two cell lines, respectively. The number of significant 
SNPs in the genome and that in the DHSs of Th1 and Th17 
are shown in Table 1. We observed a significant enrichment 
of association signals at different significance cut-offs for 
both NIDDK and WTCCC studies in DHSs regions com-
pared to the average genome (Figure 1). At a stringent sig-
nificance level (p-value less than 1×10), there were more 
than two times of association signals in the DHS regions. In 
contrast, no enrichment was observed in the negative con- 
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Table 1  A list of number of SNPs in Th1 and Th17 DHSs at different 
p-value cutoffsa) 
 
# SNPs in 
genome 
# SNPs in 
Th1 DHS 
# SNPs in 
Th17 DHS 
All SNPs 296561 14083 5378 
SNPs with p-value* less than 0.01 4002 221 79 
SNPs with p-value less than 0.001 540 35 13 
SNPs with p-value less than 0.0001 92 6 2 
a) *, The p-values are from the NIDDK GWAS study of Crohn’s dis-
ease. 
trol set. These results underscored the importance of using 
disease-specific information when incorporating functional 
annotations. 
2.2  The empirical replication rate is higher in DHSs 
The enrichment of association signals in a genomic feature 
simply means that if a SNP is randomly sampled from 
among the SNPs in the annotated regions, and another SNP 
is randomly sampled from the entire genome, the former 
one is more likely to be disease associated. However, a  
more appropriate scenario in prioritization is given two 
SNPs with similar p-values and different annotations, would 
the one with annotation be more replicable? We first used 
empirical data to answer this question. The NIDDK dataset 
is treated as the discovery panel, and the WTCCC dataset as 
the replication panel, since the latter has a larger sample 
size. A SNP is considered “replicable” if its association 
p-value is less than 0.0001 in the WTCCC dataset. As 
shown in Figure 2A, at fixed association level in the dis-
covery cohort (varying between 0.01 and 0.001), the SNPs 
in DHSs of Th1 and Th17 were both more replicable, with a 
fold change around 2. As a consequence, when selecting 
SNPs to include in the replication panel, we can apply a 
looser threshold for SNPs in DHSs and a more stringent 
threshold for SNPs outside DHSs, and obtain comparable 
replication rates in both sets. 
2.3  Theoretical investigation of the improved replica-
tion rate in DHSs  
Next, we set out to an analytical study for the observation 
that at a fixed significance level, SNPs in DHSs are more  
 
 
Figure 1  Enrichment of significant SNPs in DHSs of Th1 and Th17 cell lines. *, **, and *** represent significance levels 0.05, 0.01, and 0.001 of the 
Binomial test, respectively. 
 
Figure 2  The empirical (A) and expected (B) replication rate of selected SNPs in the genome and that in DHSs of Th1 and Th17 cell lines respectively.  
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replicable. The necessity for a theoretical framework lies in 
(i) it leads to a better understanding of the source for the 
increased replication rate in DHSs; and (ii) it provides esti-
mation of the expected replication rate for a range of priori-
tization methods. 
In a specific ranking approach of the genome-wide SNPs, 
we took the top k SNPs and considered the expected number 
of replicable SNPs among them. Here, a SNP is “replicable” 
if the corresponding p-value in the replication cohort is 
lower than a given threshold. In the Crohn’s disease study, 
we used 0.0001 as the threshold. The probability that a SNP 
is replicable depends on two factors: its effect size and the 
statistical power of the replication study. We adopted the 
non-parametric estimation of Park et al., to estimate the 
distribution of the effect sizes of associated SNPs with an-
notation and that in the whole genome (see Materials and 
methods). The effect size distributions of SNPs in Th1 and 
Th17 DHSs are slightly skewed to the right compared to the 
whole genome (Figure 3). Combined with the power calcu-
lation, the expected replication rate in DHSs and the ge-
nome can be calculated (see Materials and methods). 
In order to investigate whether or not prioritization by 
DHSs can improve the replication rate, we considered the 
following ranking approaches: (A) all SNPs that reach cer-
tain significance threshold are selected for follow-up studies. 
Here the original p-values in the NIDDK cohort ({pi,   
i=1,..., N}, N is the number of SNPs in the study) are con-
sidered, Ai ip p ; (B) only SNPs within DHSs and with 
p-values below the threshold are considered (eq. (8)); (C) 
the p-values of the SNPs within DHSs are adjusted by a 
factor of  (>1) while the p-values of the SNPs outside 
DHSs are kept intact. Then all SNPs of which the adjusted 
p-values are below the significance threshold are selected 





















   
 (9) 
Approach A represents the scenario of no prioritization, and 
approaches B and C represent different prioritization meth-
ods that incorporate annotation. Apparently, in the approach 
C, when  is very large, it reduces to the approach B. In 
particular, approach C is more practical since we want to 
loosen the inclusion criteria of SNPs in DHSs in follow-up 
experiments, but not to exclude SNPs outside DHSs with 
promising p-values (e.g., SNPs that reach genome-wide 
significance). 
The expected replication rates of the three ranking ap-
proaches can be estimated from the effect size distribution 
and the power in the WTCCC cohort. When the significance 
threshold in the NIDDK cohort was set to 0.001 (Figure 2B), 
the expected replication rate of the approach A (no prioriti-
zation is performed) was 0.065. In the approach B, the ex-
pected replication rates by DHSs in Th1 and Th17 cell lines 
were 0.131 and 0.139, respectively. Compared to the em-
pirical replication rates (Figure 2), the theoretical results 
were consistent with the empirical observation that SNPs 
within DHSs are more replicable. The higher replication 
rate of SNPs in DHSs should be attributed to an elevated 
level of effect sizes, since those SNPs have more power to 
be identified in subsequent studies. In approach C, the se-
lected SNPs are a combination of SNPs within and outside 
DHSs, and the proportion of mixing varies between 0 and 1, 
depending on the choice of ω and the p-value distribution in 
the discovery cohort. Suppose the mixing proportion of 
SNPs in DHSs is m and the expected replication rates in and 
outside DHSs are ERRB and ERRA, then the expected repli-
cation rate of approach C is 
 (1 ) .C B AERR mERR m ERR    (10) 
Please note that due to p-value adjustment, the selected 
SNPs in DHSs have larger p-values compared to those out-
side DHSs. When we fix the p-value threshold to 0.001, 
ERRA is 0.065, while ERRB varies by the choice of ω (Fig-
ure 4A). When ω is between 1 and 4, the expected replica-
tion rate in both Th1 and Th17 cell lines is greater than the 
baseline level (0.065). In other words, with proper choice of 
ω, approach C can select more SNPs without sacrificing the 
replication rate. Thus, the DHSs in Th1 and Th17 cell lines 




Figure 3  Kernel density estimation of the effect size distribution in the 
WTCCC cohort. Solid line, nominally significant SNPs in the genome; 
dashed line, nominally significant SNPs in the DHSs of Th1; dotted line, 
nominally significant SNPs in the DHSs of Th17. 
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Figure 4  The expected replication rate when varying parameters. A, The expected replication rate of approach B when varying ω. B, The expected replica-
tion rate of approach C when varying ω. 
Another key question is how much improvement can be 
expected. In theory, m can take any value between 0 and 1, 
and a larger m corresponds to a higher replication rate. In 
the Crohn’s disease study, we used empirical data to esti-
mate m. Although the DHSs in Th1 and Th17 cell lines 
cover only 4.75% and 1.81% of genomic markers, the mix-
ing proportions in these genomic regions are greater due to 
the enrichment of association signals at these sites. Actually, 
when ω is set to 4, which is the largest choice of ω with 
ERRB greater than the baseline level in the Th1 cell line, m 
is around 0.16 for the Th1 cell line, and around 0.07 for the 
Th17 cell line. The expected replication rates were 0.067 
and 0.070 for Th1 and Th17 cell lines, respectively (Figure 
4B). Thus, the improvement of replication rate was only 
moderate. A total of 62 and 24 SNPs from DHSs of Th1 and 
Th17 can be selected, resulting in four and three SNPs that 
are expected to be replicable respectively.    
2.4  Expected replication rate with larger effect size 
and larger coverage of annotations 
In the analysis in Crohn’s disease with DHS annotation, the 
improvement in replication rate was modest, which was 
limited by (i) the coverage of the annotation and (ii) the 
extent of the shift of effect size distribution. With the theo-
retical framework, we can vary these parameters and learn 
how the expected replication rate changes with them. 
We first considered the impact of effect size distribution, 
which has an effect in the expected replication rate in the 
annotation. Assume the effect size of an annotation is mul-
tiplied by λ as that in Th1 annotation (eq. (11)), the ex-
pected replication rate in approach B can be calculated 
through our theoretical model. The result is 0.164 and 0.261 
when λ is set to 2 and 3 correspondingly, and the p-value 
threshold is 0.001, compared to 0.131 in Th1 DHSs.  
 new Th1( ) ( / ).density es density es   (11) 
Next, we assume that the effect size distribution of an an-
notation is the same as that in Th1 DHSs, but the coverage 
of the annotation is increased. In this setup, ERRB is fixed, 
while the mixing proportion m will increase accordingly. 
When ω is set to 4, the mixing proportion with Th1 DHSs is 
0.16, while its coverage in the genome is 4.75%. When we 
increase the coverage to 10%, 20%, and 30%, assuming the 
number of significant SNPs changes proportionally to the 
coverage, the mixing proportion is increased to 0.30, 0.49, 
and 0.62 (Methods). As a result (eq. (10)), the overall repli-
cation rate will be improved to 0.068, 0.070, and 0.072.   
3  Discussion 
In this paper, we studied the potential of utilizing functional 
annotations of the human genome to prioritize GWAS re-
sults. The problem was formulated on Crohn’s disease and 
DHSs due to data availability, but the application to other 
traits and genomic features is straightforward. We found 
that the choice of disease specific annotation is important 
for prioritization. The expected replication rate can be im-
proved if the SNPs with annotation have a greater density at 
regions with large effect size, compared to that in the whole 
genome. However, the overall improvement may be only 
moderate, especially when only a limited number of SNPs 
can be afforded in replication studies. We proposed an ana-
lytical framework that calculates the expected replication 
rate with incorporation of functional annotations. The 
framework can not only be applied to select functional an-
notations that can improve replication rate, but also estimate 
the extent of improvement to be expected. 
There are other ways to incorporate biological infor-
mation other than the two methods we discussed here, 
which may lead to more optimized result in replication rate. 
For example, the weights of each marker can vary by the 
enrichment score of the functional annotation. Nevertheless, 
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the third ranking method captures the essence of prioritiza-
tion strategies, which is to put more confidence in SNPs 
with annotations that are believed to be relevant. There is a 
great need to develop a most informative prioritization 
method that can incorporate multiple sources of annotations.  
This work was supported in part by the National Institutes of Health (R01 
GM59507 and U01 HG005718) and the VA Cooperative Studies Program 
of the Department of Veterans Affairs, Office of Research and Develop-
ment. This study makes use of data generated by the Wellcome Trust Case 
Control Consortium. A full list of the investigators who contributed to the 
generation of the data is available from www.wtccc.org.uk. Funding for the 
project was provided by Wellcome Trust under award 076113. We also 
thank dbGaP for the association results of phs000130.v1.p1. 
1 Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, 
Collins FS, Manolio TA. Potential etiologic and functional 
implications of genome-wide association loci for human diseases and 
traits. Proc Natl Acad Sci USA, 2009, 106: 9362–9367 
2 Cantor RM, Lange K, Sinsheimer JS. Prioritizing GWAS results: a 
review of statistical methods and recommendations for their 
application. Am J Hum Genet, 2010, 86: 6–22 
3 Hou L, Zhao H. A review of post-GWAS prioritization approaches. 
Front Genet, 2013, 4: 280 
4 Minelli C, De Grandi A, Weichenberger CX, Gögele M, Modenese 
M, Attia J, Barrett JH, Boehnke M, Borsani G, Casari G, Fox CS, 
Freina T, Hicks AA, Marroni F, Parmigiani G, Pastore A, Pattaro C, 
Pfeufer A, Ruggeri F, Schwienbacher C, Taliun D, Pramstaller PP, 
Domingues FS, Thompson JR. Importance of different types of prior 
knowledge in selecting genome-wide findings for follow-up. Genet 
Epidemiol, 2013, 37: 205–213 
5 Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson 
BP, Li Y, Kurreeman FAS, Zhernakova A, Hinks A, Guiducci C, 
Chen R, Alfredsson L, Amos CI, Ardlie KG, Barton A, Bowes J, 
Brouwer E, Burtt NP, Catanese JJ, Coblyn J, Coenen MJH, 
Costenbader KH, Criswell LA, Crusius JBA, Cui J, de Bakker PIW, 
De Jager PL, Ding B, Emery P, Flynn E, Harrison P, Hocking LJ, 
Huizinga TWJ, Kastner DL, Ke X, Lee AT, Liu X, Martin P, Morgan 
AW, Padyukov L, Posthumus MD, Radstake TRDJ, Reid DM, 
Seielstad M, Seldin MF, Shadick NA, Steer S, Tak PP, Thomson W, 
van der Helm-van Mil AHM, van der Horst-Bruinsma IE, van der 
Schoot CE, van Riel PLCM, Weinblatt ME, Wilson AG, Wolbink GJ, 
Wordsworth BP, Wijmenga C, Karlson EW, Toes REM, de Vries N, 
Begovich AB, Worthington J, Siminovitch KA, Gregersen PK, 
Klareskog L, Plenge RM. Genome-wide association study meta- 
analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet, 
2010, 42: 508–514 
6 Thomas G, Jacobs KB, Kraft P, Yeager M, Wacholder S, Cox DG, 
Hankinson SE, Hutchinson A, Wang Z, Yu K, Chatterjee N, 
Garcia-Closas M, Gonzalez-Bosquet J, Prokunina-Olsson L, Orr N, 
Willett WC, Colditz GA, Ziegler RG, Berg CD, Buys SS, McCarty 
CA, Feigelson HS, Calle EE, Thun MJ, Diver R, Prentice R, Jackson 
R, Kooperberg C, Chlebowski R, Lissowska J, Peplonska B, Brinton 
LA, Sigurdson A, Doody M, Bhatti P, Alexander BH, Buring J, Lee 
IM, Vatten LJ, Hveem K, Kumle M, Hayes RB, Tucker M, Gerhard 
DS, Fraumeni JF, Hoover RN, Chanock SJ, Hunter DJ. A multistage 
genome-wide association study in breast cancer identifies two new 
risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet, 2009, 41: 
579–584 
7 The EPC. A user’s guide to the Encyclopedia of DNA Elements 
(ENCODE). PLoS Biol, 2011, 9: e1001046 
8 Chadwick LH. The NIH Roadmap Epigenomics Program data 
resource. Epigenomics, 2012, 4: 317–324 
9 Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype 
imputation method for the next generation of genome-wide 
association studies. PLoS Genet, 2009, 5: e1000529 
10 Delaneau O, Howie B, Cox Anthony J, Zagury JF, Marchini J. 
Haplotype estimation using sequencing reads. Am J Hum Genet, 
2013, 93: 687–696 
11 The 1000 Genome Project Consortium. An integrated map of genetic 
variation from 1092 human genomes. Nature, 2012, 491: 56–65 
12 Park JH, Wacholder S, Gail MH, Peters U, Jacobs KB, Chanock SJ, 
Chatterjee N. Estimation of effect size distribution from genome- 
wide association studies and implications for future discoveries. Nat 
Genet, 2010, 42: 570–575 
13 Genome-wide association study of 14,000 cases of seven common 
diseases and 3,000 shared controls. Nature, 2007, 447: 661–678 
14 Franke A, McGovern DPB, Barrett JC, Wang K, Radford-Smith GL, 
Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, Anderson CA, 
Bis JC, Bumpstead S, Ellinghaus D, Festen EM, Georges M, Green T, 
Haritunians T, Jostins L, Latiano A, Mathew CG, Montgomery GW, 
Prescott NJ, Raychaudhuri S, Rotter JI, Schumm P, Sharma Y, 
Simms LA, Taylor KD, Whiteman D, Wijmenga C, Baldassano RN, 
Barclay M, Bayless TM, Brand S, Buning C, Cohen A, Colombel J-F, 
Cottone M, Stronati L, Denson T, De Vos M, D'Inca R, Dubinsky M, 
Edwards C, Florin T, Franchimont D, Gearry R, Glas J, Van Gossum 
A, Guthery SL, Halfvarson J, Verspaget HW, Hugot J-P, Karban A, 
Laukens D, Lawrance I, Lemann M, Levine A, Libioulle C, Louis E, 
Mowat C, Newman W, Panes J, Phillips A, Proctor DD, Regueiro M, 
Russell R, Rutgeerts P, Sanderson J, Sans M, Seibold F, Steinhart AH, 
Stokkers PCF, Torkvist L, Kullak-Ublick G, Wilson D, Walters T, 
Targan SR, Brant SR, Rioux JD, D'Amato M, Weersma RK, 
Kugathasan S, Griffiths AM, Mansfield JC, Vermeire S, Duerr RH, 
Silverberg MS, Satsangi J, Schreiber S, Cho JH, Annese V, 
Hakonarson H, Daly MJ, Parkes M. Genome-wide meta-analysis 
increases to 71 the number of confirmed Crohn's disease 
susceptibility loci. Nat Genet, 2010, 42: 1118–1125 
15 Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, 
Lee JC, Philip Schumm L, Sharma Y, Anderson CA, Essers J, 
Mitrovic M, Ning K, Cleynen I, Theatre E, Spain SL, Raychaudhuri 
S, Goyette P, Wei Z, Abraham C, Achkar JP, Ahmad T, Amininejad 
L, Ananthakrishnan AN, Andersen V, Andrews JM, Baidoo L, 
Balschun T, Bampton PA, Bitton A, Boucher G, Brand S, Buning C, 
Cohain A, Cichon S, D’Amato M, De Jong D, Devaney KL, 
Dubinsky M, Edwards C, Ellinghaus D, Ferguson LR, Franchimont 
D, Fransen K, Gearry R, Georges M, Gieger C, Glas J, Haritunians T, 
Hart A, Hawkey C, Hedl M, Hu X, Karlsen TH, Kupcinskas L, 
Kugathasan S, Latiano A, Laukens D, Lawrance IC, Lees CW, Louis 
E, Mahy G, Mansfield J, Morgan AR, Mowat C, Newman W, 
Palmieri O, Ponsioen CY, Potocnik U, Prescott NJ, Regueiro M, 
Rotter JI, Russell RK, Sanderson JD, Sans M, Satsangi J, Schreiber S, 
Simms LA, Sventoraityte J, Targan SR, Taylor KD, Tremelling M, 
Verspaget HW, De Vos M, Wijmenga C, Wilson DC, Winkelmann J, 
Xavier RJ, Zeissig S, Zhang B, Zhang CK, Zhao H, Silverberg MS, 
Annese V, Hakonarson H, Brant SR, Radford-Smith G, Mathew CG, 
Rioux JD, Schadt EE, Daly MJ, Franke A, Parkes M, Vermeire S, 
Barrett JC, Cho JH. Host-microbe interactions have shaped the 
genetic architecture of inflammatory bowel disease. Nature, 2012, 
491: 119–124 
16 Brand S. Crohn’s disease: Th1, Th17 or both? The change of a 
paradigm: new immunological and genetic insights implicate Th17 
cells in the pathogenesis of Crohn’s disease. Gut, 2009, 58: 
1152–1167 
17 Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of 
inflammatory bowel diseases. Gastroenterology, 2011, 140: 1756– 
1767.e1 
18 Maurano MT, Humbert R, Rynes E, Thurman RE, Haugen E, Wang 
H, Reynolds AP, Sandstrom R, Qu H, Brody J, Shafer A, Neri F, Lee 
K, Kutyavin T, Stehling-Sun S, Johnson AK, Canfield TK, Giste E, 
Diegel M, Bates D, Hansen RS, Neph S, Sabo PJ, Heimfeld S, 
Raubitschek A, Ziegler S, Cotsapas C, Sotoodehnia N, Glass I, 
Sunyaev SR, Kaul R, Stamatoyannopoulos JA. Systematic 
 Hou L, et al.   Sci China Life Sci   November (2014) Vol.57 No.11 1079 
localization of common disease-associated variation in regulatory 
DNA. Science, 2012, 337: 1190–1195 
19 Thurman RE, Rynes E, Humbert R, Vierstra J, Maurano MT, Haugen 
E, Sheffield NC, Stergachis AB, Wang H, Vernot B, Garg K, John S, 
Sandstrom R, Bates D, Boatman L, Canfield TK, Diegel M, Dunn D, 
Ebersol AK, Frum T, Giste E, Johnson AK, Johnson EM, Kutyavin T, 
Lajoie B, Lee B K, Lee K, London D, Lotakis D, Neph S, Neri F, 
Nguyen ED, Qu H, Reynolds AP, Roach V, Safi A, Sanchez ME, 
Sanyal A, Shafer A, Simon JM, Song L, Vong S, Weaver M, Yan Y, 
Zhang Z, Zhang Z, Lenhard B, Tewari M, Dorschner MO, Hansen 
RS, Navas PA, Stamatoyannopoulos G, Iyer VR, Lieb JD, Sunyaev 
SR, Akey JM, Sabo PJ, Kaul R, Furey TS, Dekker J, Crawford GE, 
Stamatoyannopoulos JA. The accessible chromatin landscape of the 
human genome. Nature, 2012, 489: 75–82 
 
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction 
in any medium, provided the original author(s) and source are credited. 
